<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; plan</title>
	<atom:link href="http://www.tapanray.in/tag/plan/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Unleashing Pharma’s New Potential In Changing Market Dynamics</title>
		<link>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unleashing-pharmas-new-potential-in-changing-market-dynamics</link>
		<comments>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/#comments</comments>
		<pubDate>Mon, 07 Jun 2021 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote working]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TCS]]></category>
		<category><![CDATA[unleashing]]></category>
		<category><![CDATA[WFH]]></category>
		<category><![CDATA[work from home]]></category>
		<category><![CDATA[workplace]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10525</guid>
		<description><![CDATA[Several pharma majors have started pondering in this space. This is evident from several recent developments, both in India, and also in other places of the world. One such articulation can be heard from the very top of the domestic &#8230; <a href="http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India Not To Vaccinate All For Covid Control: Upsides And Unknowns</title>
		<link>http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns</link>
		<comments>http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/#comments</comments>
		<pubDate>Mon, 07 Dec 2020 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[authorization]]></category>
		<category><![CDATA[citizen]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[emergency-use]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Moderna]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Oxford]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[Prime Minister]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sputnik V]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[U.K]]></category>
		<category><![CDATA[unknowns]]></category>
		<category><![CDATA[upsides]]></category>
		<category><![CDATA[Vaccinate]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[work in progress]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10355</guid>
		<description><![CDATA[With 9.46 million cases and 137,621 deaths, India has currently the world’s second-highest number of coronavirus infections, behind only the United States, reported Reuters on December 01, 2020. Fathoming seriousness of rapidly unfolding Covid induced all round disruptions across the nation, on &#8230; <a href="http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-not-to-vaccinate-all-for-covid-control-upsides-and-unknowns/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Data-giri’: Critical For A Rewarding New Product Launch</title>
		<link>http://www.tapanray.in/data-giri-critical-for-a-rewarding-new-product-launch/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-giri-critical-for-a-rewarding-new-product-launch</link>
		<comments>http://www.tapanray.in/data-giri-critical-for-a-rewarding-new-product-launch/#comments</comments>
		<pubDate>Mon, 24 Dec 2018 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[(UCE)]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Data-giri]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Share]]></category>
		<category><![CDATA[SOC]]></category>
		<category><![CDATA[SOV]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[switch]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[UPE]]></category>
		<category><![CDATA[Voice]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9326</guid>
		<description><![CDATA[Success in new product launches is a fundamental requirement to excel in pharma business – regardless of whether the drug is innovative or a generic one. For a novel, innovative molecule, associated risks are much higher, as it carries a &#8230; <a href="http://www.tapanray.in/data-giri-critical-for-a-rewarding-new-product-launch/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-giri-critical-for-a-rewarding-new-product-launch/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Stakeholder-Mix Has Changed, But Pharma Marketing Has Not</title>
		<link>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stakeholder-mix-has-changed-but-pharma-marketing-has-not</link>
		<comments>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/#comments</comments>
		<pubDate>Mon, 13 Jun 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[captains]]></category>
		<category><![CDATA[category]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[multi-stakeholder]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recasting]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7670</guid>
		<description><![CDATA[“We try never to forget that medicine is for the people. It is not for profit. Profits follow, and if we have remembered that, they never fail to appear.” In 1952, George Wilhelm Herman Emanuel Merck, the then President of &#8230; <a href="http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma MNCs Jettison Lobbyist&#8217;s Plan: A Welcoming Development?</title>
		<link>http://www.tapanray.in/pharma-mncs-jettison-lobbyists-plan-a-welcoming-development/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-mncs-jettison-lobbyists-plan-a-welcoming-development</link>
		<comments>http://www.tapanray.in/pharma-mncs-jettison-lobbyists-plan-a-welcoming-development/#comments</comments>
		<pubDate>Tue, 21 Jan 2014 13:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aaron]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPASA]]></category>
		<category><![CDATA[jettison]]></category>
		<category><![CDATA[lobbyist]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Motsoaledi]]></category>
		<category><![CDATA[PAE]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4902</guid>
		<description><![CDATA[In my just previous blog post titled, “Big Pharma’s Satanic Plot is Genocide”: South Africa Roars, I quoted a recent interview of the Health Minister of South Africa (SA) Mr. Aaron Motsoaledi on the above plan. As reported in the &#8230; <a href="http://www.tapanray.in/pharma-mncs-jettison-lobbyists-plan-a-welcoming-development/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-mncs-jettison-lobbyists-plan-a-welcoming-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
